HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Verna Cázares-Ordoñez Selected Research

Neuroblastoma

2/2022FGFR2 loss sensitizes MYCN-amplified neuroblastoma CHP134 cells to CHK1 inhibitor-induced apoptosis.
1/2020CEP131 Abrogates CHK1 Inhibitor-Induced Replication Defects and Is Associated with Unfavorable Outcome in Neuroblastoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Verna Cázares-Ordoñez Research Topics

Disease

3Neoplasms (Cancer)
02/2022 - 09/2014
2Neuroblastoma
02/2022 - 01/2020
1Lung Diseases (Lung Disease)
12/2022
1Uterine Cervical Neoplasms (Cancer of the Cervix)
08/2015

Drug/Important Bio-Agent (IBA)

2Proteins (Proteins, Gene)FDA Link
12/2022 - 01/2020
2MicroRNAs (MicroRNA)IBA
08/2015 - 09/2014
1Pulmonary Surfactants (Pulmonary Surfactant)IBA
12/2022
1Phospholipids (Phosphatides)FDA LinkGeneric
12/2022
1LipidsIBA
12/2022
1Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA
02/2022
1Messenger RNA (mRNA)IBA
02/2022
1PF 00477736IBA
01/2020
1Cholecalciferol (Vitamin D3)FDA Link
08/2015
1Calcitriol (Calcijex)FDA LinkGeneric
08/2015
1SteroidsIBA
09/2014
1Hormones (Hormone)IBA
09/2014